代謝異常治療薬市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、治療タイプ別、地域別、競合別、2020-2030F

代謝異常治療薬の世界市場規模は2024年に744億米ドルとなり、予測期間では2030年までCAGR 7.68%で目覚ましい成長が予測されています。

代謝異常治療薬世界市場には、代謝異常の標的治療法の開発に注力する製薬およびバイオテクノロジー業界が含まれます。これらの疾患は、必須栄養素を処理・調節する体内の能力を乱すもので、糖尿病、肥満、高脂血症などの広範な疾患に加え、フェニルケトン尿症やゴーシェ病などの希少な遺伝性疾患も含まれます。

遺伝子治療、酵素補充療法、次世代減量薬などの標的治療法の進歩と相まって、世界の代謝性疾患の罹患率の上昇が市場の成長を後押ししています。大手製薬企業は研究開発や戦略的提携に多額の投資を行っています。

しかし、この分野で事業を展開する企業は、商業的可能性を最大化するために、規制の複雑さ、厳しい臨床承認プロセス、長期的な安全性への懸念に対処しなければならないです。科学的イノベーションと規制遵守をうまく融合させた企業は、代謝異常治療薬の需要拡大で有利な立場に立つことができると思われます。

主な市場促進要因

代謝異常の有病率の上昇

主な市場課題

高い開発コスト

主要市場動向

精密医療と個別化治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 代謝異常治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患の種類別（リソソーム蓄積症、糖尿病、肥満、遺伝性代謝疾患、高コレステロール血症、その他）
  • 治療の種類別（酵素補充療法、細胞移植、小分子療法、基質還元療法、遺伝子療法、薬物療法）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の代謝異常治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の代謝異常治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の代謝異常治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の代謝異常治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの代謝異常治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の代謝異常治療薬市場：SWOT分析

第14章 競合情勢

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Metabolic Disorders Therapeutics Market was valued at USD 74.40 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.68% through 2030. The Global Metabolic Disorders Therapeutics Market encompasses the pharmaceutical and biotechnology industries focused on developing targeted treatments for metabolic disorders. These conditions, which disrupt the body's ability to process and regulate essential nutrients, include widespread diseases such as diabetes, obesity, and hyperlipidemia, as well as rare genetic disorders like phenylketonuria and Gaucher's disease.

Market growth is being propelled by the rising global incidence of metabolic diseases, coupled with advancements in targeted therapies, including gene therapy, enzyme replacement therapy, and next-generation weight-loss medications. Leading pharmaceutical firms are investing heavily in R&D and strategic collaborations.

However, companies operating in this sector must address regulatory complexities, stringent clinical approval processes, and long-term safety concerns to maximize commercial potential. Firms that successfully integrate scientific innovation with regulatory compliance will be well-positioned to capitalize on the expanding demand for metabolic disorder therapeutics.

Key Market Drivers

Rising Prevalence of Metabolic Disorders

The increasing global burden of metabolic disorders is a primary force accelerating the growth of the Global Metabolic Disorders Therapeutics Market. As the incidence of diseases such as diabetes, obesity, hyperlipidemia, and rare genetic metabolic disorders rises sharply, the demand for innovative therapeutics, disease management solutions, and preventive interventions continues to grow. Several factors contribute to this trend, each reinforcing the market's expansion and creating new opportunities for pharmaceutical and biotechnology companies.

According to the IDF Diabetes Atlas (2021), 10.5% of the global adult population (ages 20-79) is living with diabetes, with nearly 50% of cases remaining undiagnosed due to limited awareness and screening gaps. Projections indicate that by 2045, the prevalence will rise to 1 in 8 adults, reaching approximately 783 million cases-a 46% increase driven by shifting demographics, urbanization, and lifestyle changes. Notably, over 90% of diabetes cases are classified as Type 2 diabetes, largely influenced by socioeconomic disparities, aging populations, environmental risk factors, and genetic predisposition. This surge in global disease burden is expected to intensify demand for advanced therapeutics, early diagnostic solutions, and digital health interventions, making diabetes management a critical priority for healthcare systems and pharmaceutical innovators.

Key Market Challenges

High Development Costs

The research and development of new therapies for metabolic disorders can be prohibitively expensive. The cost of conducting clinical trials, obtaining regulatory approvals, and ensuring safety and efficacy adds significant financial pressure to pharmaceutical and biotech companies.

Key Market Trends

Precision Medicine and Personalized Therapies

The era of one-size-fits-all treatments is giving way to precision medicine. Genetic profiling, biomarker identification, and patient-specific data are increasingly guiding treatment decisions. Tailored therapies that consider an individual's genetic and metabolic profile promise higher efficacy and reduced side effects in the management of metabolic disorders.

Key Market Players

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

Report Scope:

In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Disorders Therapeutics Market, By Disease Type:

• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia
• Others

Metabolic Disorders Therapeutics Market, By Therapy Type:

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

Metabolic Disorders Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.

Available Customizations:

Global Metabolic Disorders Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Metabolic Disorders Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
  • 5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Metabolic Disorders Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
  • 6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
  • 6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type

7. Europe Metabolic Disorders Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
  • 7.3.2. United Kingdom Metabolic Disorders Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
  • 7.3.3. Italy Metabolic Disorders Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
  • 7.3.4. France Metabolic Disorders Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
  • 7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type

8. Asia-Pacific Metabolic Disorders Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolic Disorders Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
  • 8.3.2. India Metabolic Disorders Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
  • 8.3.3. Japan Metabolic Disorders Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
  • 8.3.4. South Korea Metabolic Disorders Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
  • 8.3.5. Australia Metabolic Disorders Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type

9. South America Metabolic Disorders Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
  • 9.3.2. Argentina Metabolic Disorders Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
  • 9.3.3. Colombia Metabolic Disorders Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type

10. Middle East and Africa Metabolic Disorders Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolic Disorders Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
  • 10.3.2. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
  • 10.3.3. UAE Metabolic Disorders Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Metabolic Disorders Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Eli Lilly and Company
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. Sanofi SA
• 14.5. Merck KGaA
• 14.6. AstraZeneca PLC
• 14.7. AbbVie Inc
• 14.8. Johnson & Johnson Services, Inc
• 14.9. Amgen Inc
• 14.10.BioMarin International Limited

15. Strategic Recommendations

16. About Us & Disclaimer